Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 6 (February 20), 2008: pp. 1013-1014
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.2017

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgan, D. A.L.
Right arrow Articles by Robertson, J. F.R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgan, D. A.L.
Right arrow Articles by Robertson, J. F.R.
Related Articles
Right arrowRelated Reply
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

CORRESPONDENCE

Boost or Not

David A.L. Morgan

Department of Clinical Oncology, Nottingham University Hospitals, Nottingham, United Kingdom

John F.R. Robertson

Division of Breast Surgery, University of Nottingham, Nottingham, United Kingdom

To the Editor:

We wish to comment on the paper by Bartelink et al1 reporting a large series of patients treated with wide local excision and radiotherapy, and randomly assigned to receive either standard whole-breast irradiation (50 Gy in 25 fractions) or the same plus a boost of 16 Gy.

The boost may, statistically significantly, reduce the risk of local recurrence in patients older than 50 years, and the proportional reduction may be the same as for younger patients, but the absolute reduction in risk of recurrence in these patients is in fact only a few percent (the authors do not provide the exact figures, but this can be seen from the graphs in Fig 3 of the article).

Conversely, the use of a boost results in an increased incidence of moderate to severe fibrosis of approximately 20% (Fig 4 of the article). This obviously influences cosmesis, which is an important consideration for these women as they chose breast-conserving surgery rather than mastectomy.

In summary, only a small percentage of patients age older than 50 years receive any benefit from the boost, whereas a much larger percentage have worse results cosmetically from its use. What benefit there is—a small reduction in local recurrence—in this study has not been shown to translate into an improvement in overall survival.

Although we accept that there might be specific risk factors that could select an individual patient older than 50 years for boost due to an identifiable increased risk of local recurrence, our interpretation of these randomized data is that a boost in patients older than 50 years is certainly not warranted as the routine standard of care.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

REFERENCE

1. Bartelink H, Horiot J-C, Poortmans PM, et al: Impact of higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25:3259-3265, 2007[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Reply

  • In Reply:
    Harry Bartelink, Jean-Claude Horiot, Philip Poortmans, and Laurence Collette
    JCO 2008 26: 1014 [Full Text]

Related Article

  • Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial
    Harry Bartelink, Jean-Claude Horiot, Philip M. Poortmans, Henk Struikmans, Walter Van den Bogaert, Alain Fourquet, Jos J. Jager, Willem J. Hoogenraad, S. Bing Oei, Carla C. Wárlám-Rodenhuis, Marianne Pierart, and Laurence Collette
    JCO 2007 25: 3259-3265 [Abstract] [Full Text]



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgan, D. A.L.
Right arrow Articles by Robertson, J. F.R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgan, D. A.L.
Right arrow Articles by Robertson, J. F.R.
Related Articles
Right arrowRelated Reply
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online